Try our beta test site

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT02310763
First received: November 4, 2014
Last updated: March 7, 2017
Last verified: March 2017
  Purpose
This is a Phase 2 randomized, 2-period, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, efficacy, PK and PD of PF-06252616 administered to ambulatory boys diagnosed with Duchenne Muscular Dystrophy. Three intravenous (IV) dose levels will be investigated in a within subject dose escalating fashion. Subjects will be randomly assigned to 1 of 3 sequence groups for approximately 96 weeks (2 periods of 48 weeks each). In period 1, two of the sequence groups will receive PF-06252616 and one sequence group will receive placebo. In period 2, the placebo group will switch to PF-06252616 and the two remaining sequence groups will either receive placebo or PF-06252616. Efficacy will be based on an observed mean change from baseline on function (4 stair climb) of PF-06252616 as compared to the placebo at the end of period 1. Period 2 provides an opportunity to evaluate PK. Subjects will receive monthly IV infused doses of either PF-06252616 or placebo and will undergo safety evaluations (Laboratory, cardiac monitoring, physical exams, x-ray, MRI), functional evaluations (pulmonary function testing, 4 stair climb, range of motion, strength testing, Northstar Ambulatory Assessment, upper limb functional testing and the six minute walk test), pharmacokinetic testing and pharmacodynamic testing to evaluate changes in muscle volume (MRI).

Condition Intervention Phase
Duchenne Muscular Dystrophy
Biological: PF-06252616
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study To Evaluate The Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Pf-06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Incidence of dose limiting or intolerability treatment related AEs [ Time Frame: Baseline through 49 Weeks ]
  • Mean change from baseline on the 4 Stair Climb (4SC) as compared to placebo in seconds [ Time Frame: Baseline, 49 Weeks ]

Secondary Outcome Measures:
  • Mean change from baseline as compared to placebo of Forced Vital Capacity in liters [ Time Frame: Baseline, 17, 33 and 49 Weeks ]
  • Mean change from baseline as compared to placebo in the NSAA score [ Time Frame: Baseline, 17, 33 and 49 Weeks ]
  • Mean change from baseline as compared to placebo in the ankle range of motion in degrees [ Time Frame: Baseline, 17, 33 and 49 Weeks ]
  • Mean change from baseline as compared to placebo in the PUL score [ Time Frame: Baseline, 17, 33 and 49 Weeks ]
  • Mean change from baseline as compared to placebo in the 6MWD in meters [ Time Frame: Baseline, 17, 33 and 49 Weeks ]
  • Mean change from baseline as compared to placebo muscle strength as measured by hand held myometry in kilograms [ Time Frame: Baseline, 17, 33 and 49 Weeks ]
  • Mean change from baseline as compared to placebo in the thigh muscle volume by MRI in mm3 [ Time Frame: Baseline, 17, 33 and 49 Weeks ]
  • Area Under the Curve from Time Zero to end of dosing interval (AUCtau) of GDF-8 [ Time Frame: Baseline through 93 Weeks ]
  • Area Under the Curve, steady state from Time Zero to end of dosing interval (AUCtau,ss) of GDF-8 [ Time Frame: Baseline through Week 93 ]
  • Concentration at time 0 (pre-dose), C(0) of GDF-8 [ Time Frame: Baseline ]
  • Maximum Observed Serum Concentration at steady state (Cmax, ss) of GDF-8 [ Time Frame: Baseline through 93 Weeks ]
  • Time to Reach Maximum Observed Serum Concentration (Tmax) of GDF-8 [ Time Frame: Baseline through 93 Weeks ]
  • Observed Serum Trough Concentration at steady state (Ctrough,ss) of GDF-8 [ Time Frame: Baseline through 93 Weeks ]
  • Observed Serum Concentration steady state average (Css,av) of GDF-8 [ Time Frame: Baseline through 93 Weeks ]
  • Maximum Observed Serum Concentration (Cmax) of PF-06252616 [ Time Frame: Baseline through 93 Weeks ]
  • Time to Reach Maximum Observed Serum Concentration (Tmax) of PF-06252616 [ Time Frame: Baseline through 93 Weeks ]
  • Minimum Observed Serum Trough Concentration (Ctrough) of PF-06252616 [ Time Frame: Baseline through 93 Weeks ]
  • Serum Decay Half-Life (t1/2) of PF-06252616 [ Time Frame: Baseline through 93 Weeks ]
  • Area Under the Curve From Time Zero to Last Quantifiable Serum Concentration (AUCt) of PF-06252616 [ Time Frame: Baseline, 1, 13, 17, 29, 33 and 45 Weeks ]
  • Average Observed Serum Concentration (Cav) of PF-06252616) [ Time Frame: Baseline, 1, 13, 17, 29, 33 and 45 Weeks ]
  • Clearance (CL) of PF-06252616 [ Time Frame: Baseline, 1, 13, 17, 29, 33 and 45 Weeks ]
  • Volume of Distribution at Steady State (Vss) of PF-06252616 [ Time Frame: Baseline, 1, 13, 17, 29, 33 and 45 Weeks ]
  • Immunogenicity: Incidence of anti-drug antibody [ Time Frame: Baseline through 97 Weeks ]
  • Immunogenicity: Incidence of neutralizing antibody [ Time Frame: Baseline through 97 Weeks ]
  • Within subject change from baseline in thigh mucscle volume mm3 [ Time Frame: 97 Weeks ]

Estimated Enrollment: 105
Actual Study Start Date: November 24, 2014
Estimated Study Completion Date: May 24, 2019
Estimated Primary Completion Date: April 30, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PF-06252616
3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
Biological: PF-06252616
PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
Placebo Comparator: Placebo
Matching Placebo
Drug: Placebo

  Eligibility

Ages Eligible for Study:   6 Years to 15 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ambulatory boys age 6 to <16 years old (at the time of randomization), diagnosed with DMD. Diagnosis must be confirmed in subject's medical history and by genetic testing obtained during routine clinical care for diagnostic purposes as reported from an appropriate regulated laboratory using a clinically validated genetic test (genetic testing is not provided by the sponsor).
  2. Subjects who are able to perform the 4 stair climb in > or = 0.33 but < or =1.6 stairs/second.
  3. Subjects must be receiving glucocorticosteroids for a minimum of 6 months prior to signing informed consent. There should be no significant change (>0.2 mg/kg) in dosage or dose regimen (not related to body weight change) for at least 3 months immediately prior to signing the informed consent and a reasonable expectation that dosage and dosing regimen will not change significantly for the duration of the study.
  4. Adequate hepatic and renal function on screening laboratory assessments.
  5. No underlying disposition for iron accumulation on screening laboratory assessments.
  6. Iron content estimate on the screening liver MRI is within the normal range.

Exclusion Criteria:

  1. Subjects with known cognitive impairment or behavioral issues that would impede the ability to follow instructions.
  2. History of major surgical procedure within 6 weeks of signing the informed consent or planned surgery during the study.
  3. Any injury which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date.
  4. Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary and cardiac disease.
  5. Compromised cardiac function (left ventricular ejection fraction <55% as determined on a screening cardiac MRI or echocardiogram). Subjects may be receiving ACE (angiotensin converting enzyme) inhibitors or beta blockers, ARB (angiotensin II receptor antagonist) or aldosterone blocker/thiazide diuretic; however they must have initiated treatment more than 3 months prior to screening to ensure stable therapy.
  6. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including uncontrolled hypertension), hepatic, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  7. Documented history of iron overload including hemochromatosis, beta thalassemia major, beta thalassemia intermedia or hemolytic anemia.
  8. Unwilling or unable (eg, metal implants, requires sedation) to undergo examination with closed MRI without sedation.
  9. Participation in other studies involving investigational drug(s) for a minimum of 30 days or within 5 half lives (whichever is longer) prior to signing the informed consent and/or during study participation.
  10. Current or prior treatment with anti-myostatin, exon skipping, nonsense mutation targeted therapies ever or more than 30 days of treatment with utrophin modifiers and treatment with utrophin modifiers within 30 days prior ot signing the informed consent and/or during study participation.
  11. Current or prior treatment within the past 3 months with androgens or human growth hormone.
  12. Current treatment with immunosuppressant therapies (other than glucocorticoid steroids), aminoglycosides (eg, gentamicin), multi vitamins with iron and iron supplements and other investigational therapies (including idebenone).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02310763

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

  Show 66 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT02310763     History of Changes
Other Study ID Numbers: B5161002
2014-002072-92 ( EudraCT Number )
Study First Received: November 4, 2014
Last Updated: March 7, 2017

Keywords provided by Pfizer:
Duchenne Muscular Dystrophy, myostatin

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked

ClinicalTrials.gov processed this record on March 28, 2017